Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies

Approximately 20% of lung adenocarcinomas harbor KRAS mutations, an oncogene that drives tumorigenesis and has the ability to alter the immune system and the tumor immune microenvironment. While KRAS was considered “undruggable” for decades, specific KRAS G12C covalent inhibitors have recently emerg...

Descripción completa

Detalles Bibliográficos
Autores principales: Cucurull, Marc, Notario, Lucia, Sanchez-Cespedes, Montse, Hierro, Cinta, Estival, Anna, Carcereny, Enric, Saigí, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793278/
https://www.ncbi.nlm.nih.gov/pubmed/35096591
http://dx.doi.org/10.3389/fonc.2021.793121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793278/
https://www.ncbi.nlm.nih.gov/pubmed/35096591
http://dx.doi.org/10.3389/fonc.2021.793121

Ejemplares similares